Review



sw1990 parental cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC sw1990 parental cells
    A – D <t>SW1990</t> cells stably engineered for doxycycline-inducible regulatable sh236 KRAS-specific shRNA expression and CMV-driven constitutive expression of the various flag-tagged KRAS G12D alleles without (FK G12D ) or with discrete mutations within the back-pocket (FK G12D/L23E or FK G12D / V45D or FK G12D/V45D/L23E ) were treated for 72 h with doxycycline, lyzed and cell extracts further analyzed either by straight western-blot for the indicated read-outs ( A and C ), or by GST-cRaf-RBD pull-down to quantify GTP-loaded exogenously expressed KRAS binding ( B , upper panel), or by anti-flag co-immuno-precipitation for endogenous proteins ( D , upper panel). For ( B , D ), Input (lower panels) refer to straight western blots to assess expression levels across the conditions tested. E , F SW1990 cells stably engineered for doxycycline-inducible regulatable non targeting shNT control or sh236 KRAS-specific shRNA expression and Ubc-driven constitutive expression of the various flag-tagged KRAS G12D and KRAS G12D/V45D alleles were treated with doxycycline for either 14 days in a colony formation assay (left panel), or for 3 days only at which stage cells were lyzed and cell extracts analyzed by western-blot for the mentioned read-outs. Con.: control cells engineered from CMV-driven empty vector; SE: Short Exposure; LE: Long Exposure; a: endogenous KRAS G12D ; b: flag-tagged exogenously expressed KRAS. For ( A – F ), a minimum of three repeats has been performed with similar results; Source Data are provided as a Source Data file.
    Sw1990 Parental Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1236 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sw1990 parental cells/product/ATCC
    Average 97 stars, based on 1236 article reviews
    sw1990 parental cells - by Bioz Stars, 2026-05
    97/100 stars

    Images

    1) Product Images from "Identification and characterization of binders to a cryptic and functional pocket in KRAS"

    Article Title: Identification and characterization of binders to a cryptic and functional pocket in KRAS

    Journal: Nature Communications

    doi: 10.1038/s41467-025-65844-3

    A – D SW1990 cells stably engineered for doxycycline-inducible regulatable sh236 KRAS-specific shRNA expression and CMV-driven constitutive expression of the various flag-tagged KRAS G12D alleles without (FK G12D ) or with discrete mutations within the back-pocket (FK G12D/L23E or FK G12D / V45D or FK G12D/V45D/L23E ) were treated for 72 h with doxycycline, lyzed and cell extracts further analyzed either by straight western-blot for the indicated read-outs ( A and C ), or by GST-cRaf-RBD pull-down to quantify GTP-loaded exogenously expressed KRAS binding ( B , upper panel), or by anti-flag co-immuno-precipitation for endogenous proteins ( D , upper panel). For ( B , D ), Input (lower panels) refer to straight western blots to assess expression levels across the conditions tested. E , F SW1990 cells stably engineered for doxycycline-inducible regulatable non targeting shNT control or sh236 KRAS-specific shRNA expression and Ubc-driven constitutive expression of the various flag-tagged KRAS G12D and KRAS G12D/V45D alleles were treated with doxycycline for either 14 days in a colony formation assay (left panel), or for 3 days only at which stage cells were lyzed and cell extracts analyzed by western-blot for the mentioned read-outs. Con.: control cells engineered from CMV-driven empty vector; SE: Short Exposure; LE: Long Exposure; a: endogenous KRAS G12D ; b: flag-tagged exogenously expressed KRAS. For ( A – F ), a minimum of three repeats has been performed with similar results; Source Data are provided as a Source Data file.
    Figure Legend Snippet: A – D SW1990 cells stably engineered for doxycycline-inducible regulatable sh236 KRAS-specific shRNA expression and CMV-driven constitutive expression of the various flag-tagged KRAS G12D alleles without (FK G12D ) or with discrete mutations within the back-pocket (FK G12D/L23E or FK G12D / V45D or FK G12D/V45D/L23E ) were treated for 72 h with doxycycline, lyzed and cell extracts further analyzed either by straight western-blot for the indicated read-outs ( A and C ), or by GST-cRaf-RBD pull-down to quantify GTP-loaded exogenously expressed KRAS binding ( B , upper panel), or by anti-flag co-immuno-precipitation for endogenous proteins ( D , upper panel). For ( B , D ), Input (lower panels) refer to straight western blots to assess expression levels across the conditions tested. E , F SW1990 cells stably engineered for doxycycline-inducible regulatable non targeting shNT control or sh236 KRAS-specific shRNA expression and Ubc-driven constitutive expression of the various flag-tagged KRAS G12D and KRAS G12D/V45D alleles were treated with doxycycline for either 14 days in a colony formation assay (left panel), or for 3 days only at which stage cells were lyzed and cell extracts analyzed by western-blot for the mentioned read-outs. Con.: control cells engineered from CMV-driven empty vector; SE: Short Exposure; LE: Long Exposure; a: endogenous KRAS G12D ; b: flag-tagged exogenously expressed KRAS. For ( A – F ), a minimum of three repeats has been performed with similar results; Source Data are provided as a Source Data file.

    Techniques Used: Stable Transfection, shRNA, Expressing, Western Blot, Binding Assay, Immunoprecipitation, Control, Colony Assay, Plasmid Preparation



    Similar Products

    sw1990 parental cells  (ATCC)
    97
    ATCC sw1990 parental cells
    A – D <t>SW1990</t> cells stably engineered for doxycycline-inducible regulatable sh236 KRAS-specific shRNA expression and CMV-driven constitutive expression of the various flag-tagged KRAS G12D alleles without (FK G12D ) or with discrete mutations within the back-pocket (FK G12D/L23E or FK G12D / V45D or FK G12D/V45D/L23E ) were treated for 72 h with doxycycline, lyzed and cell extracts further analyzed either by straight western-blot for the indicated read-outs ( A and C ), or by GST-cRaf-RBD pull-down to quantify GTP-loaded exogenously expressed KRAS binding ( B , upper panel), or by anti-flag co-immuno-precipitation for endogenous proteins ( D , upper panel). For ( B , D ), Input (lower panels) refer to straight western blots to assess expression levels across the conditions tested. E , F SW1990 cells stably engineered for doxycycline-inducible regulatable non targeting shNT control or sh236 KRAS-specific shRNA expression and Ubc-driven constitutive expression of the various flag-tagged KRAS G12D and KRAS G12D/V45D alleles were treated with doxycycline for either 14 days in a colony formation assay (left panel), or for 3 days only at which stage cells were lyzed and cell extracts analyzed by western-blot for the mentioned read-outs. Con.: control cells engineered from CMV-driven empty vector; SE: Short Exposure; LE: Long Exposure; a: endogenous KRAS G12D ; b: flag-tagged exogenously expressed KRAS. For ( A – F ), a minimum of three repeats has been performed with similar results; Source Data are provided as a Source Data file.
    Sw1990 Parental Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sw1990 parental cells/product/ATCC
    Average 97 stars, based on 1 article reviews
    sw1990 parental cells - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    A – D SW1990 cells stably engineered for doxycycline-inducible regulatable sh236 KRAS-specific shRNA expression and CMV-driven constitutive expression of the various flag-tagged KRAS G12D alleles without (FK G12D ) or with discrete mutations within the back-pocket (FK G12D/L23E or FK G12D / V45D or FK G12D/V45D/L23E ) were treated for 72 h with doxycycline, lyzed and cell extracts further analyzed either by straight western-blot for the indicated read-outs ( A and C ), or by GST-cRaf-RBD pull-down to quantify GTP-loaded exogenously expressed KRAS binding ( B , upper panel), or by anti-flag co-immuno-precipitation for endogenous proteins ( D , upper panel). For ( B , D ), Input (lower panels) refer to straight western blots to assess expression levels across the conditions tested. E , F SW1990 cells stably engineered for doxycycline-inducible regulatable non targeting shNT control or sh236 KRAS-specific shRNA expression and Ubc-driven constitutive expression of the various flag-tagged KRAS G12D and KRAS G12D/V45D alleles were treated with doxycycline for either 14 days in a colony formation assay (left panel), or for 3 days only at which stage cells were lyzed and cell extracts analyzed by western-blot for the mentioned read-outs. Con.: control cells engineered from CMV-driven empty vector; SE: Short Exposure; LE: Long Exposure; a: endogenous KRAS G12D ; b: flag-tagged exogenously expressed KRAS. For ( A – F ), a minimum of three repeats has been performed with similar results; Source Data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Identification and characterization of binders to a cryptic and functional pocket in KRAS

    doi: 10.1038/s41467-025-65844-3

    Figure Lengend Snippet: A – D SW1990 cells stably engineered for doxycycline-inducible regulatable sh236 KRAS-specific shRNA expression and CMV-driven constitutive expression of the various flag-tagged KRAS G12D alleles without (FK G12D ) or with discrete mutations within the back-pocket (FK G12D/L23E or FK G12D / V45D or FK G12D/V45D/L23E ) were treated for 72 h with doxycycline, lyzed and cell extracts further analyzed either by straight western-blot for the indicated read-outs ( A and C ), or by GST-cRaf-RBD pull-down to quantify GTP-loaded exogenously expressed KRAS binding ( B , upper panel), or by anti-flag co-immuno-precipitation for endogenous proteins ( D , upper panel). For ( B , D ), Input (lower panels) refer to straight western blots to assess expression levels across the conditions tested. E , F SW1990 cells stably engineered for doxycycline-inducible regulatable non targeting shNT control or sh236 KRAS-specific shRNA expression and Ubc-driven constitutive expression of the various flag-tagged KRAS G12D and KRAS G12D/V45D alleles were treated with doxycycline for either 14 days in a colony formation assay (left panel), or for 3 days only at which stage cells were lyzed and cell extracts analyzed by western-blot for the mentioned read-outs. Con.: control cells engineered from CMV-driven empty vector; SE: Short Exposure; LE: Long Exposure; a: endogenous KRAS G12D ; b: flag-tagged exogenously expressed KRAS. For ( A – F ), a minimum of three repeats has been performed with similar results; Source Data are provided as a Source Data file.

    Article Snippet: SW1990 (ATCC #CRL-2172) and all the engineered lines from the SW1990 parental cells were cultured in RPMI 1640 media with Glutamax, supplemented with 10% FBS, 1 mM Sodium pyruvate, 10 mM HEPES at 37 °C with 5% CO 2 .

    Techniques: Stable Transfection, shRNA, Expressing, Western Blot, Binding Assay, Immunoprecipitation, Control, Colony Assay, Plasmid Preparation